Company Strategy & Focus - Amphastar operates with a "Three-H" focus: High Quality, High Efficiency, and High Technology, aiming for high net income margins[8, 15, 17] - The company employs a dual-strategy growth model, combining organic pipeline development with strategic acquisitions[8, 13, 14] - Amphastar is strategically shifting its pipeline towards proprietary products and biosimilars, projecting a change from 63% generic, 16% biosimilar, and 21% proprietary in 2021 to 15% generic, 35% biosimilar, and 50% proprietary in 2026[19, 20] Financial Performance & R&D Investment - Amphastar's revenue has grown steadily, reaching $732 million in 2024[15, 47] - Adjusted net income margin has increased significantly, reaching 27.4% in 2024[15, 16] - The company has invested approximately $351 million in self-funded R&D over the recent 5 years[26] Pipeline & Product Portfolio - Key pipeline products include AMP-002 (Iron Sucrose), with +$500 million in IQVIA sales and AMP-017 (Inhalation) with +$1.3 billion in IQVIA sales[29] - The company has an interchangeable insulin pipeline covering the full spectrum of insulin, targeting a $4.5 billion market[31, 32] - Amphastar in-licensed three new peptide assets (AMP-105, -107, -109) targeting oncology and ophthalmology, with a combined market potential exceeding $60 billion[34, 37] Key Products & Sales - BAQSIMI® sales are projected to reach a peak of $250 million to $275 million, with an estimated $2.00 to $2.50 incremental adjusted EPS at peak[54, 59] - Primatene MIST® annual sales reached $102 million in 2024, with forecasts of high single-digit growth in 2025[61, 62]

Financial Performance - Originations reached $6.5 billion in funded volume[17] - Total revenue was $323.3 million on $7.0 billion of pull-through weighted lock volume[17] - Adjusted revenue amounted to $325.2 million[19] - The company experienced an adjusted net loss of $2.8 million and an adjusted EBITDA of $48.8 million[17] - Unrestricted cash stood at $459 million[19] Operational Highlights - The servicing portfolio increased to $118.2 billion[17] - The organic refinance consumer direct recapture rate was 65%[17] - Purchase mix accounted for 60% of originations[19] - The company serves approximately 440,000 clients[10] Outlook - Q4 2025 pull-through weighted rate lock volume is projected to be between $6.0 billion and $8.0 billion[44] - Q4 2025 origination volume is expected to range from $6.5 billion to $8.5 billion[44]

Financial Performance - Revenue reached $479.5 million, reflecting an 8% sequential increase, driven by new launches in Performance Suite and Specialty Tech & Services[6] - Adjusted EBITDA was $39.0 million, a 23% year-over-year growth[6] - The company narrowed its revenue outlook for 2026 to between $1.87 billion and $1.88 billion[6] - Adjusted EBITDA outlook narrowed to between $144 million and $154 million[6] Capital Allocation - Evolent Health had $116.7 million in cash and cash equivalents as of September 30, 2025, with $47.5 million in revolver availability[6] - The company issued $166.8 million of 4.50% 2031 Notes and repaid $167.4 million of 2025 Notes[6] - Evolent repurchased 4.4 million shares of common stock for $40.0 million[6] - Exchanged $175.0 million of Series A Preferred Stock for second lien term loan on similar terms, with interest now tax deductible[6] - Period-end net leverage was 6.7x on LTM Adjusted EBITDA of $136.0 million[6] Business Growth - Announced two new revenue arrangements, one in the Performance Suite and one in the Technology and Services Suite, bringing YTD total to 13, forecasting approximately $2.5 billion for 2026[6]

Q3 2025 Financial Performance - Revenue for Q3 2025 was $634.5 million, compared to $687.5 million in Q3 2024, a decrease of 7.7%[9] - Gross profit for Q3 2025 was $184.4 million, with a gross margin of 29.1%, compared to $213.1 million and 31.0% respectively in Q3 2024[9] - Operating income for Q3 2025 was $47.6 million, resulting in an operating margin of 7.5%, compared to $22.3 million and 3.2% respectively in Q3 2024[9] - Net income for Q3 2025 was $29.3 million, or $0.76 per share, compared to $7.0 million, or $0.18 per share in Q3 2024[9] - Adjusted EBITDA for Q3 2025 was $57.5 million, with an adjusted EBITDA margin of 9.1%, compared to $73.9 million and 10.7% respectively in Q3 2024[9] Segment Performance - Nurse & Allied Solutions revenue was $361 million in Q3 2025, a 9.5% decrease year-over-year[9] - Physician & Leadership Solutions revenue was $175 million in Q3 2025, a 1.3% decrease year-over-year[9] - Technology & Workforce Solutions revenue was $95 million in Q3 2025, an 11.8% decrease year-over-year[9] Balance Sheet and Cash Flow - Cash and cash equivalents totaled $53 million as of September 30, 2025, compared to $42 million as of June 30, 2025[35] - Net cash provided by operating activities was $23 million in Q3 2025, compared to $67 million in Q3 2024[37] - Free cash flow was $15 million in Q3 2025, compared to $47 million in Q3 2024[37] Q4 2025 Financial Guidance - Consolidated revenue is projected to be between $715 million and $730 million[39] - Gross margin is expected to be between 25.5% and 26.0%[39] - Adjusted EBITDA margin is projected to be between 6.8% and 7.3%[39]

Century Aluminum Company 3 rd Quarter Earnings Call November 6, 2025 Cautionary Statement Certain statements in this presentation, and those made by Century Aluminum Company management on the quarterly conference call, relate to future events and expectations and are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "believe," "expect," "hope," "target," "anticipate," "intend," "plan," "seek," "estimate," "potential," "project," "scheduled ...

Third quarter 2025 earnings presentation November 6, 2025 Cautionary statement regarding forward-looking statements This presentation includes forward-looking statements that reflect our current views with respect to future events and financial performance. Such statements are provided under the "safe harbor" protection of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements that do not relate solely to historical or current facts, and can generally be iden ...

FiscalNote Powering Better Policy Decisions with AI-Driven Insights CORPORATE OVERVIEW November 6, 2025 © 2025 FiscalNote fiscalnote.com Footnote: Unless otherwise indicated, data presented herein is as of September 30, 2025. 1 Safe Harbor Statement Safe Harbor Statement Certain statements herein may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements generally relate to future events or FiscalNote's future financial ...

FINANCIAL RESULTS: Q3:2025 SLIDE SUPPLEMENT • Welcome • Business Highlights and Updates Stephen Gunstream, President and Chief Executive Officer • Financial Results and 2025 Outlook Matt Lowell, Chief Financial Officer • Q&A Forward-looking statements and use of non-GAAP financial measures Statements in this presentation about future expectations, plans, and prospects, as well as any other statements regarding matters that are not historical facts, may constitute "forward-looking statements." These statemen ...

Q3 2025 Financial Performance - Revenue increased to $269 million, a $8 million or 3% increase compared to Q3 2024[8] - Gross profit increased to $68 million, a $23 million or 51% increase compared to Q3 2024[8, 10] - Operational EBITDA significantly increased by $28 million to $29 million, a 2800% increase compared to Q3 2024[10] - Adjusted Operational EBITDA increased by $24 million to $27 million, an 800% increase compared to Q3 2024[10] YTD September 2025 Financial Performance - Revenue increased slightly to $779 million, a $2 million or 0% increase compared to YTD 2024[12] - Gross profit increased to $165 million, a $13 million or 9% increase compared to YTD 2024[12] - Operational EBITDA increased by $23 million to $40 million, a 135% increase compared to YTD 2024[12] - Adjusted Operational EBITDA increased by $21 million to $39 million, a 117% increase compared to YTD 2024[12] Advanced Materials and Chemicals (AM&C) - AM&C revenue increased by 15% compared to the prior year quarter[9] Kodak U.S. Retirement Income Plan - Expected proceeds from reversion increased from $500 million to $600 million, consisting of approximately $450 million in cash and $150 million in hedge funds[8]

Financial Performance - Revenue reached $147.5 million, representing a 5.3% year-over-year growth[12, 38] - Adjusted EBITDA margin expanded by 140 bps year-over-year to 31.5%[13] - Pro Forma Last Twelve Months (LTM) Revenue was $585.1 million, with a 7.6% year-over-year growth[14] - Pro Forma annualized Total Payments Volume (TPV) is estimated at $13.0 billion[14] - Levered Free Cash Flow (LFCF) for Q3 2025 was $23.3 million[46] - Adjusted Unlevered Free Cash Flow (aUFCF) for Q3 2025 was $32.3 million, a 8.8% year-over-year decline[45] Customer Growth and Cross-Selling - 276,000 total customers are enabled with more than one solution, a 33% year-over-year increase[17, 18] - 116,000 customers actively utilize more than one solution, reflecting a 32% year-over-year growth[17, 18] Payments and Acquisitions - Payments revenue grew by 6.0% year-over-year, driven by Total Payments Volume (TPV) growth[13, 21] - The company closed the acquisition of AI agent ZyraTalk, an AI agentic platform[13] Outlook - Q4 2025 revenue is projected to be between $148 million and $152 million[49] - Q4 2025 Adjusted EBITDA is expected to be between $39.5 million and $41.5 million[49] - Full year 2025 revenue is guided to be between $584 million and $592 million[49] - Full year 2025 Adjusted EBITDA is guided to be between $174.5 million and $179.5 million[49]